Abstract 54P
Background
Brain tumors are the most common tumors causing dysfunctions and the most fatal types of cancers. Patients with Parkinson’s disease (PD), the second most common neurodegenerative disorders, may be at high risk for brain tumors due to synucleins expression, chronic neuro-inflammation, levodopa therapy and radiations, but there is still controversy especially in Asia. Therefore, we conducted a nationwide population-based cohort study to assess the risk of brain tumors in patients with PD in South Korea.
Methods
We analyzed 52,009 patients diagnosed with PD between 2010 and 2015, and the age- and sex-matched 260,045 individuals without PD (mean age: 71.3 years; 40.8% men), using the data from the Korean National Health Insurance Database. Patients previously diagnosed with cancer were excluded. The cohorts were followed up to 2016 for cancer development. Cox proportional hazards regression models were used to evaluate the association between PD and brain cancer.
Results
Patients with PD had a higher brain cancer risk (hazard ratio [HR], 1.73; 95% confidence interval [CI], 1.05–2.85) in female patients with PD than in those without PD after adjustment for multiple covariates. There was no significant difference in brain tumor incidence between the two cohorts in men (HR, 1.02; 95% CI, 0.52-2.02).
Conclusions
This nationwide population-based cohort study revealed that patients with PD had higher risk of brain tumors than those without PD in Korea. Further studies are required to determine the underlying mechanisms.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
221P - Comparative analysis of first-line immune checkpoint inhibitor versus carboplatin-based chemotherapy for cisplatin-ineligible metastatic urothelial carcinoma: A multicenter, retrospective real-world evidence
Presenter: Hsiang‐Lan Lai
Session: Poster display session
Resources:
Abstract
222P - Does tumor grade really improve the prognostic ability of the staging system for men with penile cancer: A SEER database analysis
Presenter: Ravi Kanodia
Session: Poster display session
Resources:
Abstract
223TiP - EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
Presenter: Daniel Petrylak
Session: Poster display session
Resources:
Abstract
230P - Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort
Presenter: Lingying Wu
Session: Poster display session
Resources:
Abstract
231P - Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
Presenter: David SP Tan
Session: Poster display session
Resources:
Abstract
233P - Incorporation of correlative studies in ovarian cancers in the era of precision medicine: Assessment of accountability and utility
Presenter: Nadia Hitchen
Session: Poster display session
Resources:
Abstract
234P - Implementation of mainstream BRCA testing in epithelial ovarian cancer in a tertiary centre
Presenter: Edbert Wong
Session: Poster display session
Resources:
Abstract
235P - The efficacy of radiation therapy in ovarian carcinoma: A propensity score analysis of a population-based study
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
236P - Front-line maintenance therapy for platinum-sensitive ovarian cancer: What’s next PARP inhibitors?
Presenter: Han Gong
Session: Poster display session
Resources:
Abstract
237P - PARP inhibitor in platinum resistant ovarian cancer: Single center real world experience
Presenter: Saphalta Baghmar
Session: Poster display session
Resources:
Abstract